5-Bromo-4-fluoro-2-hydrazinylbenzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Bromo-4-fluoro-2-hydrazinylbenzoic acid
• 英文别名: 5-bromo-4-fluoro-2-hydrazinylbenzoic acid
• 化学式: C₇H₆BrFN₂O₂
• 分子量: 249.04
• InChiKey: FMJSGDMQIUVSKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] PYRAZOLES AS MODULATORS OF HEMOGLOBIN<br/>[FR] PYRAZOLES UTILISÉS UTILISÉS COMME MODULATEURS DE L'HÉMOGLOBINE
  申请人：PFIZER

  公开号：WO2020109994A1

  公开（公告）日：2020-06-04

  The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

  这项发明涉及吡唑衍生物，其在医学上的应用，含有它们的组合物，其制备方法以及用于这些方法的中间体。更具体地，该发明涉及式(I)的HbS调节剂或其互变异构体，或者该调节剂或其互变异构体的药学上可接受的盐，其中X、Y、R2和R3如描述中所定义。HbS调节剂在治疗包括镰状细胞病（SCD）在内的广泛疾病中可能是有用的。
• [EN] SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] PYRAZOLOQUINAZOLINONES ET PYRROLOQUINAZOLINONES SUBSTITUÉES EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE DU GROUPE II
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2016046404A1

  公开（公告）日：2016-03-31

  The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGlu Rs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

  本发明提供了通式(I)的吡唑并喹唑啉酮和吡咯并喹唑啉酮衍生物以及含有它们的药物组合物。此外，式(I)的化合物及其组合物被提供用于治疗和/或预防与谷氨酸能信号传导和/或功能改变相关的病症，以及可以通过改变哺乳动物中的谷氨酸水平或信号传导而受影响的病症。这些通式(I)的吡唑并喹唑啉酮和吡咯并喹唑啉酮衍生物可以作为神经系统中对谷氨酸敏感的受体调节剂，特别是作为代谢型谷氨酸受体(mGluRs)的调节剂，这使得它们特别适合用于治疗和/或预防急性和慢性神经和/或精神疾病。
• CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160009701A1

  公开（公告）日：2016-01-14

  The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及咔唑化合物，包括本发明化合物的药学上可接受的组合物以及使用该组合物治疗各种疾病的方法。
• Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
  申请人：Domain Therapeutics

  公开号：EP3000814A1

  公开（公告）日：2016-03-30

  The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. These pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

  本发明提供通式（I）的吡唑喹唑啉酮和吡咯喹唑啉酮衍生物以及含有它们的药物组合物。此外，本发明提供的式(I)化合物和含有它们的组合物可用于治疗和/或预防与谷氨酸能信号传导和/或功能改变有关的疾病，和/或可受哺乳动物体内谷氨酸水平或信号传导改变影响的疾病。这些通式（I）的吡唑并喹唑啉酮和吡咯并喹唑啉酮衍生物可作为对谷氨酸敏感的神经系统受体的调节剂，特别是作为代谢型谷氨酸受体（mGluRs）的调节剂，这使它们特别适用于治疗和/或预防急性和慢性神经和/或精神疾病。
• Chemical compounds
  申请人：Pfizer Inc.

  公开号：US11014908B2

  公开（公告）日：2021-05-25

  The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

  本发明涉及吡唑衍生物、吡唑衍生物在医药中的用途、含有吡唑衍生物的组合物、吡唑衍生物的制备工艺以及用于此类工艺的中间体。 本发明尤其涉及式 (I) 的 HbS 调节剂 或其同系物，或所述调节剂或其同系物的药学上可接受的盐，其中 X、Y、R2 和 R3 如描述中所定义。 HbS 调节剂可用于治疗多种疾病，包括镰状细胞病（SCD）。